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Abstract
Background: The durability of off-treatment virologic responses has not been fully elucidated in chronic hepatitis B
(CHB) patients who have previously achieved complete virologic suppression with nucleos(t)ide analog (NA) therapy. This
study aimed to assess off-treatment virologic relapse rates and to characterize the outcomes of subsequent re-treatment
in CHB patients who have discontinued oral NA following complete virologic suppression.
Methods: Ninety-five CHB patients who showed complete virologic suppression were withdrawn from NAs: entecavir,
lamivudine, and clevudine in 67, 15, and 13 patients, respectively. Consolidation therapy was given for 6 and 12 months
for HBeAg-positive and -negative CHB, respectively, before cessation. Virologic relapse was managed with the same NA
that had induced complete virologic response before discontinuation.
Results: The cumulative rates of virologic relapse at 12 and 24 months were 73.8% and 87.1%, respectively. The relapse
rates were independent of HBeAg positivity, HBeAg seroconversion, and type of oral NA. In a multivariate analysis,
duration of oral NA therapy was the only significant predicting factor associated with off-treatment virologic relapse.
Although the majority of patients regained complete virologic suppression, some patients did not respond to
re-treatment with the initial NA and developed genotypic resistance.
Conclusions: NA consolidation therapy for 6 and 12 months is associated with high off-treatment virologic relapse in
HBeAg-positive and -negative CHB patients, respectively. Drugs with high genetic barriers to resistance should be
considered as a rescue therapy for off-treatment relapse in CHB.
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Background
The goal of oral nucleos(t)ide analog (NA) therapy for
chronic hepatitis B (CHB) is to suppress hepatitis B virus
(HBV) replication in a sustained manner, preventing dis-
ease progression to decompensated cirrhosis and hepa-
tocellular carcinoma (HCC) [1-5]. However, the duration
of oral NA treatment required once complete virologic
suppression is achieved has not been conclusively estab-
lished. Although loss of HBsAg is the ideal endpoint
associated with sustained off-treatment virologic sup-
pression [6], HBsAg is cleared in a minority of CHB pa-
tients after antiviral therapy; only 5.6–11% of patients
treated with pegylated interferon alpha clear HBsAg
[7,8], and the probability of clearance is even lower with
oral NA therapy [6,9]. HBeAg loss and/or seroconver-
sion has been widely used as a surrogate endpoint of
CHB therapy, and several practice guidelines suggest that
oral NA treatment may be stopped after 6–12 months of
consolidation therapy following HBeAg seroconversion
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[4,5,10,11]. However, the study of off-treatment virologic
response (VR) has been somewhat neglected. Although
previous reports indicate that HBeAg seroconversion may
not be durable [12-15], these data are from trials with lami-
vudine, a drug which is no longer recommended as initial
therapy because of high resistance rates. Entecavir is widely
used as a first-line therapy for CHB, but little is known
about off-treatment VR. It is also yet to be elucidated
whether re-treatment with the same oral NA can success-
fully re-induce complete VR.
The aims of this study were to assess off-treatment vi-
rologic relapse rates, identify predictive factors in CHB
patients who achieved complete VR with NA therapy,
particularly in those treated with entecavir, and to




Our study was a retrospective observational study car-
ried out in a university-affiliated tertiary hospital in
Seongnam, South Korea. Korean patients with CHB who
had been on NA therapy and met the stopping criteria
(described below) were eligible for discontinuation of
oral NA therapy. Diagnosis of combined liver cirrhosis
was made based on biopsy or a combination of clinical
findings indicating the presence of portal hypertension.
HCC was screened for and excluded throughout study
period. The risk of viral reactivation was fully ex-
plained and discussed prior to cessation of medication.
Patients who eventually stopped NA were identified
through the hospital’s electronic medical record system
(BESTCare) [16].
Stopping criteria
The stopping criteria were as follows: for HBeAg-
positive patients, at least 6 months of consolidation
therapy after achieving HBeAg loss and complete VR
(see below) [5,13]; for HBeAg-negative patients, complete
VR maintained for at least 12 months by consolidation
therapy [11]. Exclusion criteria were: 1) total treat-
ment duration <12 months; 2) decompensated cirrhosis;
3) patients who had received corticosteroid or anticancer
chemotherapy; 4) patients who had comorbidities such as
hepatitis C virus or human immunodeficiency virus in-
fection, alcoholic liver disease, or autoimmune hepatitis.
Definition of responses
After withdrawal of oral NA, conventional liver biochemis-
try, HBV serology, and serum HBV DNA levels were moni-
tored every 1–3 months. Virologic relapse was defined as
reappearance of serum HBV DNA >60 IU/mL, regardless
of biochemical response. When virologic relapse was con-
firmed, a second course of treatment was considered with
same oral NA that induced complete VR prior to discon-
tinuation. The response to treatment was classified as fol-
lows: complete VR, a decrease in serum HBV DNA to
undetectable levels, as determined by real-time quantitative
polymerase chain reaction (PCR) assay (<60 IU/mL) or
HBV DNA qualitative test; partial VR, a decrease in HBV
DNA by >2 log10 IU/mL, but still detectable despite oral
NA therapy for more than 6 months [17]; non-response, a
decrease in serum HBV DNA by <2 log10 IU/mL after at
least 6 months of therapy [5]. The Ethics Committee of the
Seoul National University Bundang Hospital approved this
study (IRB No. B-1205/156-113).
Statistical analysis
Continuous variables were expressed as mean (±standard
deviation) or median (range) where appropriate, and
the Student’s t-test or Mann–Whitney U test were used
with or without log transformation to compare two
groups. Categorical variables were compared using the
Chi-square test. Cumulative virologic relapse rates were
estimated by Kaplan–Meier analysis, and the difference
was tested by log-rank test. To identify independent
predictors for off-treatment sustained VR, multivariate
analysis was performed using binary logistic regression.
Statistical analysis was performed with SPSS 17.0 (SPSS
Inc.; Chicago, IL, USA). P-values of <0.05 were consid-
ered statistically significant.
Results
Off-treatment virologic relapse rate
Between November 2004 and May 2010, NA treatment
was prescribed to 2,736 patients with CHB. Of these,
236 patients stopped NA therapy for variable reasons
between January 2006 and February 2012. Among these,
141 patients were excluded from further analysis because
they did not meet the stopping criteria, rendering 95
CHB patients who discontinued oral NA after complete
VR eligible for final analysis. The demographic, bio-
chemical, and virologic profiles along with treatment
course are summarized in Table 1. Of the 95 patients, 79
(83.2%) experienced virologic relapse and 16 (16.8%)
patients remained in sustained remission during the me-
dian follow-up period of 22 months. Kaplan–Meier ana-
lysis showed that the relapse rates at 12 and 24 months
were 73.8% and 87.1%, respectively (Figure 1A). Relapse
rates were similar between HBeAg-positive and -negative
patients (Figure 1B). In HBeAg-positive CHB, the relapse
rate was not significantly different between patients with
HBeAg seroconversion and patients with HBeAg loss only
(Figure 1C). Different types of oral NA showed similar re-
lapse rates (Figure 1D). Antiviral treatment for <24 months
was associated with an increased virologic relapse rate
compared with longer treatment duration in HBeAg-
negative CHB patients (p = 0.031). In HBeAg-positive
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CHB, however, there was no statistically significant dif-
ference in relapse rates between treatment durations
(Figure 1E, F).
Predictors of off-treatment sustained virologic remission
Pre-treatment clinical and virologic characteristics were
not significantly different between patients with or with-
out sustained virologic remission (Table 1). However, total
treatment duration and, in cases of HBeAg-negative CHB,
additional treatment duration after HBV DNA clearance
were significantly longer in the sustained virologic remis-
sion group. Multivariate analysis with a binary logistic re-
gression model showed that treatment duration was an
independent determinant of sustained virologic remission
(odds ratio = 64.2, p = 0.042; Table 2).
Outcomes in patients with off-treatment virologic relapse
Of 79 patients with off-treatment virologic relapse, one
patient was lost to follow up and 13 patients were
followed without further antiviral therapy. These 13 pa-
tients remained in biochemical remission and HBV
DNA levels were maintained below 2,000 IU/mL. The
remaining 65 patients received the same oral NA that
had induced initial complete VR. Among them, 58 pa-
tients (89.2%) showed re-establishment of complete VR
within 1–15 months (mean treatment time to HBV DNA
loss was 3.5 months). However, three patients (4.6%)
showed only partial VR and four patients (6.2%) showed
non-response (Figure 2). Mutation analyses showed that
resistance mutations were not observed in the complete or
partial VR groups, whereas a lamivudine-resistant muta-
tion (rtM204I/V) was found in all four non-responding pa-
tients. None of the relapsing patients experienced hepatic
decompensation throughout the study period.
The clinical characteristics and outcomes of the four
non-responding patients are summarized in Table 3.
These patients had relatively high levels of HBV DNA
and experienced early relapse within 6 months. After
drug-resistant mutations were confirmed, patients who
previously received clevudine/lamivudine therapy were
given entecavir (1 mg), and patients with previous ente-
cavir therapy received combination therapy of entecavir
(1 mg) plus adefovir. Following these rescue therapies,
two patients achieved complete VR, and two patients
showed partial VR.
Discussion
One of the unresolved issues in the management of
CHB is how long oral NA must be maintained once pa-
tients have achieved complete virologic suppression.
Current American Association for the Study of Liver
Diseases (AASLD) guidelines recommend at least 6 months
Table 1 Pre-treatment characteristics and treatment duration in CHB patients with or without off-treatment sustained
virologic remission
Factors All patients Sustained virologic remission Relapse P-valuea
Number 95 16 79
Age 47 (21–76) 45 (36–63) 49 (21–76) 0.242
Male (%) 53 (55.8) 9 (56.2) 44 (55.7) 0.968
Oral nucleos(t)ide
Entecavir 67 8 59
Lamivudine 15 5 10 0.110
Clevudine 13 3 10
HBeAg (pos/neg) 41/54 6/10 35/44 0.616
HBeAb seroconversionb before NA discontinuation 24 4 20 0.659
Alanine aminotransferase, xupper limit of normal 4.9 (0.4–30.8) 7.9 (1.1–30.8) 4.3 (0.4–25.4) 0.121
Prothrombin time, INR (range) 1.1 (1.0–1. 6) 1.1 (1.0–1.5) 1.1 (1.0–1.6) 0.704
HBV DNA (log IU/ml) 6.54 (3.31–8.00) 6.47 (3.31–8.00) 6.20 (3.44–8.00) 0.146
Cirrhosis 44 (46.4) 10 (62.5) 34 (45.0) 0.155
Total treatment duration (months) 22 (12–56) 28 (14–43) 22 (12–56) 0.016
Time to undetectable HBV DNA (months) 6 (1–23) 4 (2–6) 4 (1–23) 0.908
Additional treatment after HBeAg loss (months)b 14 (6–47) 16 (11–21) 13 (6–47) 0.988
Additional treatment after HBV DNA clearancec 16 (12–40) 25 (15–40) 17 (12–40) 0.001
Values are expressed as either median (range) or number (%).
aSustained virologic remission vs. relapse.
bData from HBeAg-positive CHB patients.
cData from HBeAg-negative CHB patients.
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of additional treatment after HBeAg seroconversion [5].
However, about a quarter of patients experience relapse
within 2 years of completing 6 months of lamivudine con-
solidation [12-15]; at 4 years, the relapse rate is increased
to 82% after cessation of lamivudine [18]. In our study,
about three quarters of CHB patients demonstrated off-
treatment virologic relapse within 12 months of treatment
termination. Although we used HBeAg loss rather than
Figure 1 Cumulative off-treatment virologic relapse rate. The relapse rates at 12 and 24 months were 73.8% and 87.1%, respectively in
patients with CHB who achieved complete viral suppression with oral nucleos(t)ide analog (NA) therapy (A). The relapse rates were similar
regardless of HBeAg status (B), HBeAg seroconversion (for pre-treatment HBeAg-positive patients who subsequently lost HBeAg during
treatment) (C), and the type of oral NA: lamivudine 100 mg/day; clevudine 30 mg/day; entecavir 0.5 mg/day (D). The relapse rates were
not significantly different between HBeAg-positive patients with <24 months and >24 months of treatment (E). However, the relapse rates
were higher in HBeAg-negative patients who received >24 months of antiviral therapy compared with patients with shorter treatment
duration (F).
Table 2 Multivariate analysis for factors associated with
off-treatment sustained virologic suppression
Factors Odds ratio (95% CI) P-value




Total treatment (months) 64.20 (1.17–3530.37) 0.042
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HBeAg seroconversion as a stopping criterion, sub-
group analysis showed that the virologic relapse rates
were not different between the seroconversion and
HBeAg loss groups (Figure 1C; [13]). We believe that
the high relapse rates in our study may be ascribed
to different definitions of virologic relapse; previous studies
used higher cut-off values of HBV DNA titer (10,000–
100,000 copies/mL) whereas we used the 60 IU/mL
(300 copies/mL) cut-off, determined by sensitive real-
time PCR assays. Indeed, studies using similar cut-off
values showed similar relapse rates in HBeAg-positive
CHB [14,19,20]. These findings suggest that 6-month
consolidation therapy is insufficient for preventing viro-
logic relapse in HBeAg-positive CHB.
AASLD 2009 guidelines and European Association for
the Study of the Liver (EASL) 2012 clinical practice guide-
lines do not recommend stopping NA treatment in
HBeAg-negative CHB unless HBsAg is cleared [4,5]. These
recommendations are based on the observations that
treatment duration of less than 1 year was universally asso-
ciated with relapse [21,22]. However, viral suppression may
not have been complete at the time of treatment cessation
in these studies as the cut-off for the definition of complete
VR was relatively high (0.7 Meq/mL; 150,000 IU/mL). In-
deed, more stringent stopping criteria with extended treat-
ment duration resulted in up to 50% of remission rate in
HBeAg-negative CHB [23,24]. Asian-Pacific guidelines,
conversely, state that treatment discontinuation can be
considered after 12–24 months of consolidation therapy
[11,25]. We wanted to know the off-treatment remission
rate after achieving complete viral suppression con-
firmed by a sensitive PCR method. Our data showed that
12-month consolidation therapy after serum HBV DNA
loss was associated with high virologic relapse rates, similar
to those of HBeAg-positive CHB with 6-month consolida-
tion. Again, the high relapse rates in our study may be due
to lower cut-off levels, determined by real-time quantitative
PCR, compared with previous reports [23,24].
Figure 2 Outcomes of CHB patients who experienced off-treatment virologic relapse after achieving complete viral suppression with
oral NA. Among the 65 patients who resumed the same oral NA that had induced initial complete virologic response, 58 patients again
achieved complete VR, three patients achieved only partial VR, and four patients showed non-response. aUndetectable HBV DNA titer; bHBV DNA
decreased by >2 log, but remained detectable; cHBV DNA decreased by <2 log or increase.
Table 3 Characteristics of CHB patients who showed non-response to re-treatment with the same oral nucleos(t)ide
























Patient 1 Clevudine Positive 20,000,000 Negative 13 7 5 rtM204I Entecavir Sustained VR
Patient 2 Lamivudine Negative 2,099,619 Positive 24 18 2 rtM204I Entecavir PartialVR
Patient 3 Lamivudine Negative 257,039 Negative 20 7 3 rtM204I Entecavir Sustained VR
Patient 4 Entecavir Positive 20,000,000 Negative 33 16 6 rtM204I Entecavir + Adefovir Partial VR
aTotal duration of initial oral nucleos(t)ide analog therapy.
bAdditional treatment duration of initial oral nucleos(t)ide analog therapy after undetectable HBV DNA.
cTime to relapse after discontinuation of initial oral nucleos(t)ide analog therapy.
VR, virologic response.
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Current guidelines recommend entecavir and tenofor-
vir as first-line drugs because of their high potency, high
genetic barrier against resistance, and excellent long-
term viral suppression [4,5]. Patients in this study started
oral antiviral therapy between 2004 and 2010; however,
entecavir and tenofovir were not approved for the treat-
ment of CHB in Korea until 2008 and 2013, respectively.
Therefore, lamivudine was prescribed until 2008, after
which entecavir was chosen as a first-line NA for the
treatment of CHB, while tenoforvir was not available to
these patients at any time. Although entecavir shows
higher virologic suppression rates compared with lami-
vudine [26], off-treatment relapse was scarcely studied
compared with lamivudine. Previous reports detailed re-
lapse data after protocol-defined termination without
consolidation therapy [19,22,26,27]. We found that the
off-treatment relapse rates were similar between enteca-
vir and the less potent drug, lamivudine. Previous phase
III clevudine trials showed delayed off-treatment viro-
logic relapse [28,29] but again, the off-treatment VR rate
was similar. This result suggests that once complete vi-
rologic suppression is obtained, off-treatment remission
rates are independent of the antiviral potency of the NA
in question, and also suggests that the stopping criteria
for entecavir should be as strict as those for less potent
drugs. Because this study did not compare head-to-head
off-treatment remission rates between entecavir and other
NAs, further prospective studies with longer follow-up pe-
riods will be necessary to address this issue.
The univariate and multivariate logistic regression ana-
lyses showed that duration of NA therapy is an inde-
pendent predictor of off-treatment sustained virologic
remission in CHB. This finding is in line with previous
studies of CHB patients treated with lamivudine [13-15].
Considering the high off-treatment relapse rates in our
study, 6 months of consolidation is insufficient in HBeAg-
positive CHB patients, as recommended by the recent
EASL guidelines [4]. However, the Kaplan–Meier analysis
in our study did not show a significant difference in re-
lapse rate according to treatment duration (<24 mo
vs. >24 mo) in HBeAg-positive CHB, and consolidation
of more than 12 months did not decrease relapse rates
compared with a shorter consolidation period (data not
shown). The reason that extension of consolidation failed
to reduce virologic relapse in HBeAg-positive CHB is not
clear at present, but our finding suggests that even
longer consolidation may be necessary in this group.
Off-treatment response is more difficult to predict in
HBeAg-negative CHB because no surrogate markers are
available, except for the rare event of HBsAg loss. We
found that prolonged consolidation is more effective for
induction of sustained virologic remission in HBeAg-
negative CHB compared with HBeAg-positive disease.
Thus, we suggest that duration of oral nucleos(t)ide
therapy be no less than 2 years in HBeAg-negative CHB.
Further prospective randomized controlled studies are
needed, however, to determine the optimal duration of NA
consolidation in CHB.
Because more than 60% of patients still experience vi-
rologic relapse after more than 2 years of NA therapy in
HBeAg-negative CHB, current guidelines for long-term
antiviral maintenance until HBsAg loss may be a safe ap-
proach, especially for patients with liver cirrhosis [4,5].
However, because some patients show sustained off-
treatment virologic remission in our study (10/54, 19%)
and other reports [23,24], cessation of oral NA might
also be an clinical option in HBeAg-negative CHB pa-
tients with or without liver cirrhosis who show complete
VR for more than 2 years [25] if significant adverse
events can be prevented in relapsers. We closely moni-
tored relapsers and NAs were resumed before biochem-
ical relapse if HBV DNA increased over 2,000 IU/mL.
Although about half of our study patients had liver
cirrhosis, no hepatic decompensation was documented
after virologic relapse. A similar study regarding the off-
therapy durability of entecavir published recently re-
ported that only one patient, who did not conform to
the follow-up schedule, developed decompensation, which
was successfully managed by a second course of entecavir
treatment [30]. Thus, cessation of NAs may safely be
tried in patients with cirrhosis on the condition of close
monitoring.
There is no consensus on how to manage off-
treatment HBV relapse. Our results revealed that about
10% of patients with off-treatment relapse failed to regain
complete virologic suppression with the same NA regi-
men. Interestingly, all four patients with non-response to
the initial NA regimen developed the rtM204I mutation
during the course of secondary treatment. Therefore,
drugs with high genetic barrier should be considered as a
rescue therapy for off-treatment relapse in CHB, and
early evaluation for genotypic resistance should be con-
sidered in these patients if the initial regimen shows inad-
equate response.
A relatively small sample size is the major limitation of
our study. However, considering the current trend,
which does not recommend early termination of NAs,
results from larger prospective trials may not be readily
available. In the meantime, our data may help when
making clinical decisions where long-term maintenance
of NAs is not feasible.
Conclusion
In summary, sensitive HBV DNA assays show high off-
treatment VR rate in CHB patients who received con-
solidation therapy (6 and 12 months for HBeAg-positive
and -negative CHB, respectively). Prolonged consolidation
may reduce off-treatment relapse in HBeAg-negative CHB.
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Although most patients with virologic relapse regain
complete virologic suppression with the same drug,
some patients do not respond to re-treatment with the
initial NA and develop genotypic resistance. Therefore,
NA with a high genetic barrier should be considered as a
rescue therapy for off-treatment relapse in CHB.
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